Contato

Nossa Ciência

Publicações em artigos científicos

Dal Col, Ribas and Araldi. (2026)

Rejuvenation by Design: Building Cosmetic Products with Extracellular Vesicle Technology, the Example of Exo. Reset®

Handbook of Extracellular Vesicles – Biology, Production, and the Regulatory Road to Market; DOI: 10.5772/intechopen.1015350
Duarte et al. (2026)

Parkinson’s Disease: From Metabolism to Genetics—A Comprehensive Review

Curr. Issues Mol. Biol. 2026, 48(3), 254; DOI: 10.3390/cimb48030254
Araldi et al. (2025)

Mechanism of Action of NestaCell®: A Bioinformatics-Guided Translational Approach for Therapeutic Modulation in Huntington’s Disease

In Mesenchymal Stem Cell – Biology, Therapeutics, and Beyond, Ed. IntechOpen, London, 2025; DOI: 10.5772/intechopen.1012979
Dal Col et al. (2025)

The Transformative Impact of Extracellular Vesicles on the Cosmetics Industry: A Comprehensive Review

Cosmetics 2025, 12(5), 191; https://doi.org/10.3390/cosmetics12050191
Araldi et al. (2025)

AI-Enhanced Transcriptomic Discovery of Druggable Targets and Repurposed Therapies for Huntington’s Disease

Brain Sci. 2025, 15(8), 865, https://doi.org/10.3390/brainsci15080865
Dias-Pinto et al. (2025).

From Brain to Blood: Uncovering Potential Therapeutical Targets and Biomarkers for Huntington’s Disease Using an Integrative RNA-Seq Analytical Platform (BDASeq®)

Cells 2025, 14(13), 976; https://doi.org/10.3390/cells14130976
Alievi et al. (2025)

Preclinical In vitro evaluation of extracellular vesicles from human dental pulp stem cells for the safe and selective modulation of anaplastic thyroid carcinoma

Int. J. Mol. Sci. 2025, 26(13), 6443; DOI: 10.3390/ijms26136443
Araldi et al. (2024).

Novel pharmaceutical targets and prognostic biomarkers for Huntington’s disease: New perspectives for the drug development. Proceedings from MENA Congress for Rare Disease

16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.
Dias-Pinto et al. (2024).

BDASeq: A novel and powerful tool able to accurately discover therapeutic targets for the treatment of rare diseases.

Proceedings from MENA Congress for Rare Disease, 16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.
Dias-Pinto et al. (2024).

How does the age of control individuals hinder the identification of target genes for Huntington’s disease?

Front Genet. 20:15: 1377237. DOI: 10.3389/fgene.2024.1377237.
Teixeira et al. (2024).

Exploring the therapeutic potential of extracellular vesicles derived from human immature dental pulp cells on papillary thyroid cancer.

Int J Mol Sci, 25: 8178. DOI: 10.3390/ijms25158178.
Kerkis et al. (2024).

The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.

Front Immunol. 24:15: 1400533. DOI: 10.3389/fimmu.2024.1400533.
Kerkis et al. (2024).

Stem cells from dental pulp of deciduous teeth: Twenty years of experience. In Recent Update on Mesenchymal Stem Cells.

DOI: 10.5772/intechopen.1003850.
Araldi et al. (2024).

Pharma Intelligence applied to the research and development of cell and cell-free therapy: A new era of the medicine.

In Recent Update on Mesenchymal Stem Cells. DOI: 10.5772/intechopen.1003827.
Faustnoni-Neto et al. (2023).

Pharma Data Analytics (Pharma Intelligence): Opportunities and challenges in the multi-Omics era of drug discovery and development.

Pharmacologia, 14(1): 29-39. DOI: 10.17311/pharma.2023.29.39.
Araldi et al. (2023).

Unique transcriptional signature observed in stem cells from dental pulp of deciduous teeth produced on a large scale.

Pharmacologia 14(1): 72-95. DOI: 10.17311/pharmacologia.2023.72.95.

Prêmios Internacionais

Araldi et al. (2024).

Novel pharmaceutical targets and prognostic biomarkers for Huntington’s disease: New perspectives for the drug development. Proceedings from MENA Congress for Rare Disease

16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.
Dias-Pinto et al. (2024).

BDASeq: A novel and powerful tool able to accurately discover therapeutic targets for the treatment of rare diseases.

Proceedings from MENA Congress for Rare Disease, 16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.